Search the Newsreel

Oswal Pumps Limited Recorded A 7.2% Miss On Revenue: Analysts Are Revisiting Their Models

Is Puma Biotechnology (PBYI) a Great Value Stock Right Now?

Puma Exploration Announces Launch of Kinross Gold Corp. Drilling Program at Williams Brook

Rimouski, Québec--(Newsfile Corp. - August 12, 2026) - Puma Exploration Inc. (TSXV: PUMA) (OTCQB: PUMXF) ("Puma" or the "Company") is pleased to announce that Kinross Gold Corp. ("Kinross") has begun another round of drilling at the Williams Brook Gold Project under its Option Agreement. …

Puma Biotechnology, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:PBYI) 2026-08-10

Puma Biotechnology reported strong Q2 2026 financial results, with total revenue reaching $56.5 million, primarily driven by increased demand for NERLYNX. The company is now debt-free after repaying its Athyrium loan and has raised its full-year guidance for both product revenue and net income. …

Puma Biotechnology (PBYI) Stock Jumps On Profit Strength As Earnings Outlook Fades

Puma Biotechnology (PBYI) saw its stock jump 9.7% after reporting strong Q2 2026 earnings, driven by NERLYNX revenue and increased net income. While current profitability and raised full-year guidance are positive, analysts project weaker earnings in the future, creating a tension between present strength …

Roto Pumps Limited Reports Earnings Results for the First Quarter Ended June 30, 2026

Roto Pumps Q1 Results: Net Profit Rises 42% YoY To ₹790.91 Lakh

Puma Biotechnology (NASDAQ:PBYI) Issues Earnings Results, Beats Expectations By $0.15 EPS

Puma Biotechnology Inc (PBYI) Earnings Forecast: Future EPS & Revenue Growth Estimates

Puma Biotechnology Inc (PBYI) currently holds an earnings forecast score of 6.00, placing it 130th out of 156 companies in the Pharmaceuticals industry. Analysts have set an average price target of $5.00 for PBYI, with a range from $2.00 to $7.00. The company's next …

TD Cowen Forecasts Strong Price Appreciation for Puma Biotechnology (NASDAQ:PBYI) Stock

PBYI Q2 Earnings & Sales Beat Estimates, 2026 Guidance Raised

Shakti Pumps (India) Limited (SHAKTIPUMP.NS) stock price, news, quote and history

Puma Biotechnology, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026

Puma Biotechnology, Inc. announced its financial results for the second quarter and six months ending June 30, 2026. For the second quarter, the company saw an increase in revenue to USD 56.5 million and net income rose to USD 8.19 million. However, for the …

PUMA BIOTECHNOLOGY, INC. 2026: Revenue $56.5M, EPS $0.16— 10-Q Summary

PUMA BIOTECHNOLOGY, INC. reported strong quarterly results for 2026, with revenue reaching $56.5 million and diluted EPS of $0.16, demonstrating significant year-over-year growth. Revenue growth was driven by increased volume in core product lines and a shift towards e-commerce, while operational improvements helped streamline …

Puma Biotechnology Inc (PBYI) (Q2 2026) Earnings Call Highlights: Debt-Free Status and Raised ...

Puma Biotechnology Inc. (PBYI) reported strong Q2 2026 results, becoming debt-free and raising its full-year revenue and net income guidance. The company saw significant growth in NERLYNX sales and is advancing its alisertib clinical program, planning for new Phase III trials in 2027. Despite …

Puma Biotech (PBYI) Q2 Earnings and Revenues Top Estimates

Earnings call transcript: Puma Biotechnology tops Q2 2026 estimates as profit returns

Puma Biotechnology (PBYI) exceeded Q2 2026 revenue and earnings estimates, reporting $56.5 million in revenue and $0.16 GAAP EPS, driven by strong NERLYNX sales. The company returned to profitability after a prior quarter loss and raised its full-year 2026 guidance for net product revenue …

Puma Biotechnology Reports Second Quarter 2026 Financial Results

Raising 2026 Revenue and Net Income Guidance Based on Increased Demand for NERLYNX LOS ANGELES, August 06, 2026--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the second quarter ended June 30, 2026. Unless otherwise stated, all comparisons are for …

Concrete Pumping (NASDAQ:BBCP) Rating Lowered to "Hold" at Zacks Research

Zacks Research has downgraded Concrete Pumping (NASDAQ:BBCP) from "strong buy" to "hold" following the company's recent earnings report where it missed EPS estimates but exceeded revenue expectations. Despite the downgrade, the broader analyst consensus remains a "Moderate Buy" with a $10.25 target price. Insiders …

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - August 5, 2026

Puma Biotechnology, Inc. announced the grant of inducement restricted stock unit awards covering 35,375 shares of common stock to five new non-executive employees on August 3, 2026. These awards, granted under the company's 2017 Employment Inducement Incentive Award Plan, vest over a three-year period …

Puma Biotechnology (PBYI) Earnings Date and Reports 2026

Oswal Pumps hosts earnings call on Aug 10 to discuss Q1FY27 results

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

LOS ANGELES, August 05, 2026--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on August 3, 2026, the Compensation Committee of Puma's Board of Directors approved the grant of inducement restricted stock unit awards covering 35,375 shares of Puma common stock to …

Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2025 Financial Results

Puma Biotechnology, Inc. will host a conference call on Thursday, February 26, 2026, at 1:30 p.m. PT/4:30 p.m. ET to discuss its fourth quarter and full year 2025 financial results. The call details and webcast information are provided for investors and interested parties. The …

Puma's Subsidiary Murray Brook Minerals Acquires Mount McInnes Project

Rimouski, Québec--(Newsfile Corp. - August 4, 2026) - Puma Exploration Inc. (TSXV: PUMA) (OTCQB: PUMXF) ("Puma" or the "Company") is pleased to announce that its subsidiary Murray Brook Minerals ("MBM") (70.48% held by Puma) secured a prospective polymetallic critical minerals project in Northern New …

PUMA (XTRA:PUM) Sees Improvement Ahead Despite Sales Drop And Confirms Outlook

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. PUMA executives reported a significant sales decline alongside improved profit margins in the latest update. Management reaffirmed the full year outlook for XTRA:PUM, …

Renaissance Technologies LLC Cuts Position in Puma Biotechnology, Inc. $PBYI

Renaissance Technologies LLC reduced its stake in Puma Biotechnology (PBYI) by 8.5% in the first quarter of 2026, selling 181,400 shares but still retaining 1.94 million shares valued at approximately $12.4 million. Despite cautious analyst sentiment and insider share sales totaling $1.01 million in …

Puma Biotechnology Inc (PBYI) Valuation: PE, PB & Fair Value Analysis

Puma Biotechnology Inc (PBYI) has a current valuation score of 5.76, ranking 143 out of 155 in the Pharmaceuticals industry. The company's current P/E ratio is 15.75, which is significantly below its recent high but above its recent low. However, relevant data for P/B, …

Puma Q2 Earnings Call Highlights

Key Points Interested in Puma Se? Here are five stocks we like better. Puma's Q2 currency-adjusted sales fell 9.4%, driven by reduced mass-merchant and promotional business, weaker consumer demand, and a 14% wholesale decline. Direct-to-consumer sales rose 0.4%, with e-commerce up 1.8% and its …

Shakti Pumps Q1FY27 Revenue Surges 37.9%, PAT Falls 47% on Margin Squeeze

When Should You Buy Concrete Pumping Holdings, Inc. (NASDAQ:BBCP)?

Concrete Pumping Holdings (NASDAQ:BBCP) has seen a significant share price rise and is currently trading below its intrinsic value of $12.58 at $9.74. The company has an optimistic outlook with expected earnings growth of 44% in the coming year, suggesting it may be a …

Earnings Preview: Puma Biotech (PBYI) Q2 Earnings Expected to Decline

Puma Biotech (PBYI) is expected to report a year-over-year decline in Q2 earnings despite higher revenues for the quarter ended June 2026. The company is projected to post earnings of $0.10 per share, a 33.3% decrease, on revenues of $53.17 million, up 1.5%. Analysts …

Puma Biotechnology (PBYI) to Release Quarterly Earnings on Thursday